Skip to main content
Descovy approved as 2nd PrEP drug for HIV, with exclusions

Gilead Sciences' Descovy, or emtricitabine and tenofovir alafenamide, has gained FDA approval as the second option for pre-exposure HIV prophylaxis. The approval indicates the drug can be used to prevent the disease in transgender women and HIV-negative men who have sex with men but does not cover cisgender women.

Full Story: